Showing papers by "Ulrich Speck published in 2010"

Drug-eluting medical device

Abstract: The present invention relates to a drug-eluting medical device, in particular a balloon for angioplasty catheters with drug elution to prevent the restenosis of the vessel subjected to angioplasty More particularly, the present invention relates to a catheter balloon completely or partially coated with paclitaxel in hydrated crystalline form or in hydrated solvated crystalline form, having an immediate release and bioavailability of a therapeutically effective amount of paclitaxel at the site of intervention The balloon can be made of a polyether-polyamide block copolymer, or a polyester amide, or polyamide-12

Advances on drug-coated balloons.

Abstract: During the last decades considerable advances have been made in intravascular interventions for the treatment of coronary and peripheral arterial disease. However, long-term outcome remains an area of concern in many applications. Restenosis is still a challenge in endovascular medicine and has thus been referred to as the Achilles' heel of percutaneous intervention. Therefore, novel strategies have been developed to overcome this problem. These include drug-eluting stents, though still associated with stent thrombosis and in-stent restenosis, and the more recently introduced non-stent based local drug delivery systems, especially the paclitaxel-eluting balloon. Results of several preclinical and clinical studies indicate that short-term exposure of injured arteries to paclitaxel eluted from regular PTA and PTCA balloons may be sufficient to reduce late lumen loss and restenosis rates during a critical period of time after angioplasty of diseased coronary and peripheral arteries. Although the number of published trials and patients treated is still limited, available data seem to prove that restenosis inhibition by immediate drug release is feasible. This article reviews the rationale for the use of paclitaxel-coated balloons, data from preclinical and clinical studies, and the perspective of drug-coated balloons in peripheral arterial disease.

Improved formulations for drug-coated medical devices

Abstract: The present invention is related to a medical device carrying at least on a portion of its surface at least one oxidation-insensitive drug or oxidation-insensitive polymer-free drug preparation and at least one lipophilic antioxidant at a ratio of 3-100% by weight of the at least one antioxidant in relation to 100 % by weight of the drug, wherein the at least one oxidation-insensitive drug is selected of taxanes, thalidomide, statins, corticoids and lipophilic derivatives of corticoids, and the at least one lipophilic antioxidant is selected of nordihydroguaiarectic acid, resveratrol and propyl gallate, and wherein scoring or cutting balloons as medical devices are excluded.

Response to Letter Regarding Article, "Paclitaxel-Coated Balloon Catheter Versus Paclitaxel-Coated Stent for the Treatment of Coronary In-Stent Restenosis"

Abstract: We appreciate the comments by Dr Alfonso and colleagues on the Paclitaxel-Eluting PTCA-Balloon Catheter in Coronary Artery Disease II (PEPCAD II) trial. Intracoronary radiation was the first successful treatment option for in-stent restenosis avoiding the stent-in-stent approach. However, implantation of a second (drug-eluting) stent has since become the first treatment option for in-stent restenosis. The implantation of a drug-eluting stent in a restenotic stent results in better acute lumen gain and lower restenosis rates compared with conventional balloon angioplasty or brachytherapy.1,2 The main determinant of restenosis after coronary stent implantation is neointimal hyperplasia. Other factors such as elastic vessel recoil and negative remodeling have no relevant impact on this scenario. Therefore, late lumen loss has been accepted as the most important …

Formulations d'enrobage améliorées pour cathéters à ballonnet d'entaille ou de coupe

Abstract: La presente invention concerne des catheters a ballonnet d'entaille ou de coupe portant au moins sur une partie de leur surface au moins un medicament resistant a l'oxydation ou une preparation medicamenteuse resistante a l'oxydation ne contenant pas de polymere et au moins un antioxydant lipophile dans une proportion comprise entre 3 et 100 % en poids dudit au moins un antioxydant lipophile pour 100 % en poids du medicament. Ledit au moins un medicament resistant a l'oxydation utilise est choisi dans le groupe constitue de taxanes, de thalidomide, de statines, de corticoides et de derives lipophiles de corticoides, et ledit au moins un antioxydant lipophile est choisi dans le groupe constitue d'acide nordihydroguaiaretique, de resveratrol et de gallate de propyle.